S-ClassAbout S-Class
M
MCKAI Stock Diagnostic Report
McKesson to acquire Precision Medicine Group for ~$2.25 billion
McKesson has decided to acquire Precision Medicine Group for approximately $2.25 billion.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$873.7899780273438Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support810.88 — echo this pre-calculated value verbatim, do NOT change it
Near-Term Resistance912.50 — echo this pre-calculated value verbatim, do NOT change it
02
FUNDAMENTALS
Financial & Fundamental Analysis
The acquisition of Precision Medicine Group, valued at approximately $2.25 billion, is a strategic M&A aimed at strengthening core business capabilities, and it is being conducted within a manageable financial burden relative to the current stock price and market capitalization.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $873.79 is positioned between the 20-day low of $810.88 and the high of $912.50, and the trading volume indicator (0.57x) is low, so it is necessary to check for additional volume inflow when attempting to break through the resistance level.
Support810.88 — echo this pre-calculated value verbatim, do NOT change it
Resistance912.50 — echo this pre-calculated value verbatim, do NOT change it
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Secured momentum for diversification of the healthcare segment portfolio and expansion of the specialized diagnostics and treatment pipeline through the acquisition of Precision Medicine Group.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-25)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.